140 related articles for article (PubMed ID: 38530080)
21. Sintilimab-Induced Myocarditis in a Patient with Gastric Cancer: A Case Report and Literature Review.
Liu X; Zeng Z; Cao J; Li X; Muhetaer M; Jin Z; Cai H; Lu Z
J Cardiovasc Dev Dis; 2023 Oct; 10(10):. PubMed ID: 37887869
[TBL] [Abstract][Full Text] [Related]
22. Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study.
Tasaki Y; Sugiyama Y; Hamamoto S; Naiki T; Uemura T; Yokota K; Kawakita D; Nakamura M; Ogawa R; Shimura T; Mimura Y; Hotta Y; Odagiri K; Ito N; Iida M; Kimura Y; Komatsu H; Kataoka H; Takiguchi S; Morita A; Iwasaki S; Okuda K; Niimi A; Yasui T; Furukawa-Hibi Y
Cancer Med; 2023 Dec; 12(24):21666-21679. PubMed ID: 37986680
[TBL] [Abstract][Full Text] [Related]
23. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
24. A rare case of eosinophilic gastritis induced by nivolumab therapy for metastatic melanoma.
Tsuji A; Hiramatsu K; Namikawa S; Yamamoto A; Midori Y; Murata Y; Tanaka T; Nosaka T; Naito T; Takahashi K; Ofuji K; Matsuda H; Ohtani M; Imamura Y; Iino S; Hasegawa M; Nakamoto Y
Clin J Gastroenterol; 2022 Oct; 15(5):876-880. PubMed ID: 35978213
[TBL] [Abstract][Full Text] [Related]
25. PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study.
Huang G; Liu S; Dong J; Xi X; Kong R; Li W; Du Q
Front Pharmacol; 2022; 13():974376. PubMed ID: 36438818
[No Abstract] [Full Text] [Related]
26. Immune-related adverse events and outcomes among pan-cancer patients receiving immune checkpoint inhibitors: A monocentric real-world observational study.
Ge X; Jiang W; Li H; Wu Y; Li X; Cui S
Cancer Med; 2023 Sep; 12(18):18491-18502. PubMed ID: 37564011
[TBL] [Abstract][Full Text] [Related]
27. Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma.
Yang H; Ma Q; Sun Y; Zhang K; Xing Y; Li H
Front Oncol; 2022; 12():1065137. PubMed ID: 36620577
[TBL] [Abstract][Full Text] [Related]
28. The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review.
Machado AP; Ratliff H; Abdelwahab A; Vohra MH; Kuang A; Shatila M; Khan MA; Shafi MA; Thomas AS; Philpott J; Alhalabi O; Wang Y
J Cancer; 2023; 14(16):2956-2963. PubMed ID: 37859810
[No Abstract] [Full Text] [Related]
29. Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case report and review of the literature.
Yan J; Ma N; Qiao WL; Liu KQ; Liu DW; Wang Y; Qiao TT; Hao XQ; Zheng MD
Ann Transl Med; 2022 Dec; 10(24):1411. PubMed ID: 36660611
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.
Simonaggio A; Michot JM; Voisin AL; Le Pavec J; Collins M; Lallart A; Cengizalp G; Vozy A; Laparra A; Varga A; Hollebecque A; Champiat S; Marabelle A; Massard C; Lambotte O
JAMA Oncol; 2019 Sep; 5(9):1310-1317. PubMed ID: 31169866
[TBL] [Abstract][Full Text] [Related]
31. Treatment of steroid-refractory immune checkpoint Inhibitor-induced intestinal pseudo-obstruction with infliximab.
Dai C; Huang YH
Rev Esp Enferm Dig; 2023 Jul; ():. PubMed ID: 37449519
[TBL] [Abstract][Full Text] [Related]
32. A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma.
Zheng S; Zhang H; Hu B; Zhou J; Wen L; Li M
Heliyon; 2023 Jun; 9(6):e16874. PubMed ID: 37342584
[TBL] [Abstract][Full Text] [Related]
33. Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer.
Yu Y; Wang S; Su N; Pan S; Tu B; Zhao J; Shen Y; Qiu Q; Liu X; Luan J; Wang FS; Meng F; Shi M
Front Oncol; 2022; 12():906824. PubMed ID: 35756643
[TBL] [Abstract][Full Text] [Related]
34. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors.
de Malet A; Antoni G; Collins M; Soularue E; Marthey L; Vaysse T; Coutzac C; Chaput N; Mateus C; Robert C; Carbonnel F
Eur J Cancer; 2019 Jan; 106():106-114. PubMed ID: 30476730
[TBL] [Abstract][Full Text] [Related]
35. Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis.
Molife C; Brnabic A; Stefaniak VJ; Belger MA; Gruver K; Chen JV; Souri S; Blumenschein GR
Immunotherapy; 2023 Mar; 15(4):293-309. PubMed ID: 36748406
[TBL] [Abstract][Full Text] [Related]
36. PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review.
Yin N; Liu X; Ye X; Song W; Lu J; Chen X
Front Oncol; 2022; 12():961266. PubMed ID: 36119464
[TBL] [Abstract][Full Text] [Related]
37. Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors.
Wang J; Ma Y; Lin H; Wang J; Cao B
BMC Immunol; 2024 Jan; 25(1):8. PubMed ID: 38267897
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
[TBL] [Abstract][Full Text] [Related]
39. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
Verspohl SH; Holderried T; Behning C; Brossart P; Schäfer VS
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006963. PubMed ID: 33912248
[TBL] [Abstract][Full Text] [Related]
40. Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review.
Zhou S; Zhang Z; Feng X; Zhao C; Jiang L
Front Pharmacol; 2023; 14():1276788. PubMed ID: 38161699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]